Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CASP1 | P29466 | 2/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | GALR3 | O60755 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1897113 | 0.84 | ERN1 (0.47) | ERN1ALDH1A1HPGDHTTTSHR | |
| SCHEMBL26620876 | 0.81 | ERN1 (0.48) | ERN1ALDH1A1HPGDHTTTSHR | |
| Formaldehyde SCHEMBL28004393 | 0.81 | GABRA1 (0.61) | ERN1ALDH1A1HPGDHTTTSHR | |
| SCHEMBL16011566 | 0.80 | FFAR4 (0.36) | ERN1ALDH1A1HPGDHTTTSHR | |
| SCHEMBL547469 | 0.80 | GABRA1 (0.66) | ERN1ALDH1A1HPGDHTTTSHR | |
| SCHEMBL28879850 | 0.79 | HSP90AA1 (0.41) | ERN1ALDH1A1HPGDHTTALOX15 | |
| SCHEMBL4665771 | 0.79 | EGFR (0.46) | ALDH1A1HPGDHTTGFERALOX15 | |
| SCHEMBL6029792 | 0.78 | PRKCI (0.53) | ALDH1A1HPGDHTTTSHRALOX15 | |
| SCHEMBL29939053 | 0.78 | PRKCI (0.53) | ALDH1A1HPGDHTTTSHRALOX15 | |
| SCHEMBL14139155 | 0.77 | HTT (0.60) | ALDH1A1HPGDHTTTSHRGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025019587-A1 | SENOTHERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2025-01-23 | — | — | WO | disclosed |
| EP-4412605-A1 | FLAVONOID DERIVATIVES WITH GABAA RECEPTOR ACTIVITY AND METHODS OF USE | Rutgers, the State University of New Jersey (US) | 2024-08-14 | — | — | EP | disclosed |
| US-11911353-B2 | Fatty acid synthase inhibitor and application thereof | JIANGNAN UNIVERSITY (CN) | 2024-02-27 | — | — | US | disclosed |
| WO-2023059802-A1 | FLAVONOID DERIVATIVES WITH GABAA RECEPTOR ACTIVITY AND METHODS OF USE | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-04-13 | — | — | WO | disclosed |
| EP-4041238-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| EP-4025211-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | Trevena, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021046183-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | TREVENA, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| US-20210046027-A1 | Fatty Acid Synthase Inhibitor and Application Thereof | JIANGNAN UNIVERSITY (CN) | 2021-02-18 | — | — | US | disclosed |
| WO-2020248327-A1 | FATTY ACID SYNTHASE INHIBITOR AND USE THEREOF | 江南大学 | 2020-12-17 | — | — | WO | disclosed |
| WO-2010021680-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| EP-2074103-A1 | 6-PHENYLPYRIMIDINONES AS PIM MODULATORS | Exelixis, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008147547-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008133955-A1 | 6-PHENYLPYRIMIDINONES AS PIM MODULATORS | EXELIXIS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| EP-1863755-A1 | SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES | Merck & Co., Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006102067-A1 | SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES | MERCK & CO., INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| EP-1692124-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | Wyeth (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005061477-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH (US) | 2005-07-07 | — | — | WO | disclosed |
| EP-1412327-A2 | INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE | LG Biomedical Institute (US) | 2004-04-28 | — | — | EP | disclosed |
| WO-2002096867-A2 | INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE | LG BIOMEDICAL INSTITUTE (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11911353-B2 | Fatty acid synthase inhibitor and application thereof | FASN, SCD, FADS2 | ERN1 2353/4885ALDH1A1 1287/4885HPGD 1309/4885 |
| US-20210046027-A1 | Fatty Acid Synthase Inhibitor and Application Thereof | FASN, SCD, FADS2 | ERN1 2353/4885ALDH1A1 1287/4885HPGD 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.